The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A placing on the cards atm ?...
The following statement is from last year after the last placing.
The net proceeds from the Placing will be used to strengthen the Company's balance sheet as partnering discussions progress and provide working capital to continue to develop the Company's portfolio of early-stage, high-value small molecule programmes. The net proceeds of the Placing are expected to provide the Company with at least twelve months working capital.
Interesting SP movements on both ETX and C4XD. Both were driven down over the past 6-9 months, only to now see a strong rebound
Looks to me like things are afoot with some decent sized trades going through today and over the last few weeks.
Personally I think this should be a stonewall MBO - it just takes one of the deals to come off and they would make a fortune. I reckon the market would take a 40p MBO price. From what I understand these new molecules dont reinvent the wheel they have just created a better mousetrap. This should increase the chances of going to full aproval although nothing is guaranteed. Then we have the deals which could emerge over the next few weeks/months and dwarf the other ones.
Nice MALT-1 inhibitor update this morning, preclinical work producing very encouraging results.
https://www.londonstockexchange.com/news-article/C4XD/malt-1-inhibitor-programme-update/15980055
Something’s kicked this into life today!
I added a couple of weeks ago, SP is so depressed and devoid of reality
Nice few buys coming in at the moment after the results.Would be great if the director’s bought a few at these all time low prices.
There is no need for a fund raising - plenty of cash through to early 2024 and other milestones just around the corner, let alone more new deals.
This company is a giveaway at this price - I believe the BoD will take it private at some stage and make a potential packet if just one of the current (let alone future) drug deals comes in. The market has got this all wrong in my view.
Please do elaborate as to why you think this.................
This is from the year end accounts, revealed in Dec:
The Group had net assets at 31 July 2022 of £11.8 million (2021: £19.3m). Cash and cash equivalents of £5.1 million (2021: £17.1m) were improved post balance sheet by proceeds from the Placing of £5.7million and receipt of both the Sanofi milestone debtor of €3million and the prior year R&D tax credit of £2.1million.
Both cash and costs continue to be prudently and tightly managed.
These financial statements have been prepared on a going concern basis, notwithstanding a consolidated operating loss for the year ended 31 July 2022 of £10.5 million (2021: £5.9m), revenues of £2.7 million (2021: £5.6m) and net cash used in operating activities of £12.1 million (2021: £3.1m). The Directors consider this to be appropriate for the following reasons:
The Board has prepared a number of cash flow forecasts for the period to 31 July 2024. Each of these show cash resource until March 2024, being 15 months from the date of signing the financial statements.
Should the company not receive any revenues from existing or new deals in the forecast period, a cash shortfall will arise in early 2024. The Board considers they are able to take reasonable mitigating action, which includes but is not limited to a reduction in expenditure on certain discretionary research programmes to focus purely on commercialising earlier stage drug molecules, and reducing other discretionary administrative expenditure, which would enable the Group and Company to continue to operate within its existing cash resources during the forecast period without the need for additional funding.
Based on cash and yearly spending
Based on what?
Can’t help but feel a placing is round the corner
https://clinicaltrials.gov/ct2/show/NCT05694533?term=c4x&draw=2&rank=3
Another trial underway then
I found this very interesting in helping myself understand the benefits of this approach.
“Even if our primary endpoint was not achieved, there's still information in that data that can help us as we think about the next trial we might want to do. It could be that we want to test this drug in a different population. It could be that we're thinking about other drugs that we might want to be testing. Post-hoc analyses are questions that we try to answer with our data after the study had finished and was not the intent of that particular study”
In a post-hoc analysis of a clinical trial, researchers will often further divide data to see if the drug had benefits for certain groups. Consider an example where the initial data for a trial has shown no benefit in the group that received the drug when compared to a placebo group. A researcher conducting a post-hoc analysis might look at only people who are under a certain age, or only people of a certain sex, and find that there is evidence that in this smaller group, that participants did appear to decline slower or survive longer.
A cracking RNS that probably will fall completely under the radar of most.
The pharma industry spend a fortune on post-hoc analysis of clinical trial data and I wonder how many good drugs fail clinical trials and end up on the shelf because they didn't know what to look for? The potential for the PatientSeek platform both to help with design and recruitment for clinical trials and post-hoc analysis will be very attractive commercially.
No idea ( can not see notes bar ) why I bought in 2021 , I see they recovered to 42p 4th January 2022 .
Less likely to of missed that if I had held on ( D ) .
I see there was a placing 11th August 2022 @ 25p no OO .
Topped up 11am for 16.65p 2% down today ( D ) brokers platform which was not allowed when I i first purchased these 24th August 2021.
( Wi ) That buy was at 30.03p showing as 43% down on the platform . ( I make it 45% down )
Took a slice in SCLP an hour before looks a good transfer of funds at midday this up a little from buy and SCLP down from the sale .
Still holding here and suspect this is a long term stock, awaiting next news !!
Dannatt
I'm asking myself the same questions. I suspect it is a question of patience. I am hoping they don't need to raise any funds due to cash in bank and upfront payments. It's one of those stocks that could come out with a fantastic RNS at any moment based on their potential partnerships. Am happy to carry the loss and accumulate now and again.
As you say, short term is confusing but I remain bullish that this company could come up with some significant innovation leading to amazing partnerships.
Relentless selling over the last two months but no RNS notification.Very strange.One million just sold.Is the seller finally out !! I don’t understand why the share price is down here with all the potential C4x offers.Am I missing something !!
Yes, obviously very early days but excellent news. Given that they're already generating preclinical activity comparable to J&J's Safimaltib, this comment from Nick Ray bodes well for the potential of the final selected candidate:-
'Showing activity comparable to the industry's lead clinical compound with our first compound in this key xenograft model, coupled with the range of improved compounds following behind, gives us confidence in nominating candidate-quality molecules within the next six months'
Their tech really does appear to give them an edge, huge potential here but definitely requires patience as the timeframes involved are quite lengthy. Bottom draw for all the right reasons.
DYOR
Also just noticed that the macd has turned positive. Indicating buy now. I guess that’s why the Algo bot turned off no trade below 18 from the algo bot since Monday